Promising efficacy of oral nano-silymarin formulation on prevention of vancomycin-induced nephrotoxicity: a randomized, triple-blinded, placebo-controlled clinical trial
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-025-04469-1 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Vahid Soleimani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, P.O. Box, Mashhad, 91775-1365, Iran. Hauptthemen laut MEDLINE: Vancomycin, Anti-Bacterial Agents, Acute Kidney Injury, Silymarin. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
Vancomycin is widely used for methicillin-resistant Staphylococcus aureus infections. However, it is associated with nephrotoxicity, which is mostly induced by the creation of free radicals in the kidney. Several studies indicated the antioxidant effect of silymarin, particularly nano-formulations with high oral bioavailability. The aim of this study was to evaluate the potential preventive effects of silymarin against vancomycin-induced nephrotoxicity. In this randomized, triple-blinded, placebo-controlled clinical trial, 60 patients who fulfilled the inclusion criteria were randomly assigned to placebo and nano-silymarin (Sinalive® 70 mg twice daily) groups in 1:1 ratio, and received them for a maximum of 14 days beside vancomycin. Patients' serum creatinine (Scr) and urea and incidence of AKI were assessed on days 3, 7, 10, and 14. The trough level of vancomycin was evaluated 30 min before the fourth dose of vancomycin. AKI incidence was significantly lower in the nano-silymarin group (P < 0.001). The comparison of serum creatinine between the placebo and treatment group showed no significant difference on days 0, 3, 7, and 14; but it was significant on days 10 (P = 0.045). The same finding was found about urea serum levels (P = 0.005 and .016, on days 10 and 14 respectively). Moreover, Scr and urea levels increased considerably in the placebo group during the study (P < 0.001) but not in the silymarin group. Our data suggested that nano-silymarin can be nephroprotective and has a preventive effect against vancomycin nephrotoxicity. However, further human studies are needed to prove these effects. It was registered at the Iranian Registry of Clinical Trials (IRCT20200408046990N9, 2022-04-06).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, P.O. Box, Mashhad, 91775-1365, Iran.
- Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, University of Medical Sciences, Mashhad, Iran.
- Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. karimig@mums.ac.ir.
- Pharmaceutical Research Center, Faculty of Pharmacy, Mashhad University of Medical Sciences, P.O. Box, Mashhad, 91775-1365, Iran. karimig@mums.ac.ir.
- Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, P.O. Box, Mashhad, 91775-1365, Iran. elyasis@mums.ac.ir.
ORCID-Profile: Sepideh Elyasi
Zitieren
APA
Soleimani, V., Khodashahi, R., Arian, M., Tavanaee, A., Omidkhoda, N., Karimi, G., & Elyasi, S. (2026). Promising efficacy of oral nano-silymarin formulation on prevention of vancomycin-induced nephrotoxicity: a randomized, triple-blinded, placebo-controlled clinical trial. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04469-1
Vancouver
Soleimani V, Khodashahi R, Arian M, Tavanaee A, Omidkhoda N, Karimi G, et al. Promising efficacy of oral nano-silymarin formulation on prevention of vancomycin-induced nephrotoxicity: a randomized, triple-blinded, placebo-controlled clinical trial. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04469-1
BibTeX
@article{Soleimani2026,
author = {Soleimani, Vahid and Khodashahi, Rozita and Arian, Mahnaz and Tavanaee, Ashraf and Omidkhoda, Navid and Karimi, Gholamreza and Elyasi, Sepideh},
title = {Promising efficacy of oral nano-silymarin formulation on prevention of vancomycin-induced nephrotoxicity: a randomized, triple-blinded, placebo-controlled clinical trial},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-025-04469-1}
}
EUVIMED